MapLight Therapeutics, Inc.
MPLTDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How MPLT's past catalysts played out
ML-007C-MA
Psychosis Associated With Alzheimer's Disease
ML-004 (IR)/(ER) tablet
Autism Spectrum Disorder
ML-007C-MA BID
Schizophrenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ML-007C-MA | Phase 2 | Psychosis Associated With Alzheimer's Disease | - | - |
ML-004 (IR)/(ER) tablet | Phase 2 | Autism Spectrum Disorder | - | - |
ML-007C-MA BID | Phase 2 | Schizophrenia | - | - |
Frequently asked questions
What is in MapLight Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in MapLight Therapeutics, Inc.'s (MPLT) pipeline across Phase 2. Its lead program is ML-007C-MA (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MapLight Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for MapLight Therapeutics, Inc. (MPLT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MPLT biotech catalysts?→
Add MPLT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MapLight Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.